RT Journal Article
SR Electronic
T1 International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study
JF Thorax
JO Thorax
FD BMJ Publishing Group Ltd and British Thoracic Society
SP 378
OP 390
DO 10.1136/thoraxjnl-2020-216555
VO 77
IS 4
A1 Araghi, Marzieh
A1 Fidler-Benaoudia, Miranda
A1 Arnold, Melina
A1 Rutherford, Mark
A1 Bardot, Aude
A1 Ferlay, Jacques
A1 Bucher, Oliver
A1 De, Prithwish
A1 Engholm, Gerda
A1 Gavin, Anna
A1 Kozie, Serena
A1 Little, Alana
A1 Møller, Bjørn
A1 St Jacques, Nathalie
A1 Tervonen, Hanna
A1 Walsh, Paul
A1 Woods, Ryan
A1 O'Connell, Dianne L
A1 Baldwin, David
A1 Elwood, Mark
A1 Siesling, Sabine
A1 Bray, Freddie
A1 Soerjomataram, Isabelle
A1 ICBP SURVMARK-2 Local Leads
A1 ICBP SURVMARK-2 Academic Reference Group
A1 
YR 2022
UL http://thorax.bmj.com/content/77/4/378.abstract
AB Introduction Lung cancer has a poor prognosis that varies internationally when assessed by the two major histological subgroups (non-small cell (NSCLC) and small cell (SCLC)).Method 236 114 NSCLC and 43 167 SCLC cases diagnosed during 2010–2014 in Australia, Canada, Denmark, Ireland, New Zealand, Norway and the UK were included in the analyses. One-year and 3-year age-standardised net survival (NS) was estimated by sex, histological type, stage and country.Results One-year and 3-year NS was consistently higher for Canada and Norway, and lower for the UK, New Zealand and Ireland, irrespective of stage at diagnosis. Three-year NS for NSCLC ranged from 19.7% for the UK to 27.1% for Canada for men and was consistently higher for women (25.3% in the UK; 35.0% in Canada) partly because men were diagnosed at more advanced stages. International differences in survival for NSCLC were largest for regional stage and smallest at the advanced stage. For SCLC, 3-year NS also showed a clear female advantage with the highest being for Canada (13.8% for women; 9.1% for men) and Norway (12.8% for women; 9.7% for men).Conclusion Distribution of stage at diagnosis among lung cancer cases differed by sex, histological subtype and country, which may partly explain observed survival differences. Yet, survival differences were also observed within stages, suggesting that quality of treatment, healthcare system factors and prevalence of comorbid conditions may also influence survival. Other possible explanations include differences in data collection practice, as well as differences in histological verification, staging and coding across jurisdictions.Data may be obtained from a third party and are not publicly available. Data contain sensitive and personal information and can be obtained from the cancer registries listed as the local leads in the manuscript.